We are now on the verge of viewing effector molecules and other regulatory sites as therapeutic targets for the amelioration of human and animal disease. The recognition, for example, that mutant proteins are frequently misrouted molecules, rather than functionally defective ones, changes our approach to "inborn errors of metabolism" and offers new approaches for pharmacological discovery, based on rescue of receptors, ion channels and enzymes with pharmacoperones. Ion channels, regulators of G-protein signaling and enzymes engaged in regulation, now present opportunities for drug development.
The state of our art also benefits by the availability of superior tools that allow measurement of interactions and afford unprecedented insight into the biomolecular interactions that present novel approaches to drug design.
"synopsis" may belong to another edition of this title.
G-Protein Coupled receptors (GPCRs) and other receptors are significant targets for drug discovery, due to their roles in fundamental physiological processes. Among these roles are: regulation of growth, food intake, reproduction, water balance, sensory perception, blood pressure and heart rate. GPCR-directed drugs account for approximately $40 billion in sales and, of drugs at market, approximately 70% target GPCR function.
The availability of combinatorial chemistry coupled with high throughput screening techniques have facilitated discovery of peptidic and non-peptidic ligands of membrane receptors. Mutant receptor models have revealed their role in health and disease and provided insight to new therapeutic approaches, based on control of protein trafficking. Understanding receptor-receptor interactions has provided one mechanism for receptor cross-talk and revealed unexpected interactions.
The completion of the human genome has identified a new source of therapeutic targets: "orphan receptors" with unknown functions and yet-to-be discovered ligands. Some orphans have now been identified as ghrelin, nociceptin, apelin, and urocortin. This finding, along with important technologies to develop ligands with desirable characteristics, including peptidomimetics is likely to further accelerate interest in this area.
"About this title" may belong to another edition of this title.
Seller: Antiquariat Carl Wegner, Berlin, B, Germany
Hardcover. 8°, Original hardcover with XV, 202 pages, color illustrations. In good condition. -- Original-Pappband mit XV, 202 Seiten, farbig bebildert. Sauberer, guter Zustand. -- Bitte Portokosten außerhalb EU erfragen! / Please ask for postage costs outside EU! / S ' il vous plait demander des frais de port en dehors de l ' UE! // Bitte beachten Sie auch unsere Fotos! / Please also note our photos! / Veuillez noter nos photos -- Leuchtender Herbstbeginn! Wie wäre es mit einem guten Buch? Bei uns werden Sie fündig, stöbern Sie in unserem Ladengeschäft oder online. -- Wir kaufen Ihre werthaltigen Bücher! Biol. Seller Inventory # 437360
Seller: Romtrade Corp., STERLING HEIGHTS, MI, U.S.A.
Condition: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide. Seller Inventory # ABBB-10610
Seller: Basi6 International, Irving, TX, U.S.A.
Condition: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service. Seller Inventory # ABEOCT25-240371
Seller: Books Puddle, Woodside, NY, U.S.A.
Condition: New. pp. xvi + 202 1st Edition. Seller Inventory # 26302959
Seller: Majestic Books, Hounslow, United Kingdom
Condition: New. pp. xvi + 202. Seller Inventory # 7545008
Quantity: 4 available
Seller: SMASS Sellers, IRVING, TX, U.S.A.
Condition: New. Brand New Original US Edition. Customer service! Satisfaction Guaranteed. Seller Inventory # SNTA-10610
Seller: Ammareal, Morangis, France
Hardcover. Condition: Très bon. Ancien livre de bibliothèque avec équipements. Edition 2006. Ammareal reverse jusqu'à 15% du prix net de cet article à des organisations caritatives. ENGLISH DESCRIPTION Book Condition: Used, Very good. Former library book. Edition 2006. Ammareal gives back up to 15% of this item's net price to charity organizations. Seller Inventory # H-630-629
Seller: Biblios, Frankfurt am main, HESSE, Germany
Condition: New. pp. xvi + 202. Seller Inventory # 18302949
Seller: Ria Christie Collections, Uxbridge, United Kingdom
Condition: New. In English. Seller Inventory # ria9783540344469_new
Quantity: Over 20 available
Seller: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germany
Buch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This book describes the current state of knowledge in receptor function in the development of new drugs. Science is on the verge of viewing effector molecules and other regulatory sites as therapeutic targets for the amelioration of human and animal disease. The book reviews the availability of state-of-the-art tools that allow measurement of interactions and afford unprecedented insight into the biomolecular interactions that present novel approaches to drug design. 220 pp. Englisch. Seller Inventory # 9783540344469